CY1124824T1 - Κολοβωμενη γλυκοπρωτεϊνη g του ιου του απλου ερπητα 2 - Google Patents

Κολοβωμενη γλυκοπρωτεϊνη g του ιου του απλου ερπητα 2

Info

Publication number
CY1124824T1
CY1124824T1 CY20211101118T CY211101118T CY1124824T1 CY 1124824 T1 CY1124824 T1 CY 1124824T1 CY 20211101118 T CY20211101118 T CY 20211101118T CY 211101118 T CY211101118 T CY 211101118T CY 1124824 T1 CY1124824 T1 CY 1124824T1
Authority
CY
Cyprus
Prior art keywords
truncated
truncated version
simplus
herpes
seq
Prior art date
Application number
CY20211101118T
Other languages
English (en)
Inventor
Jan-Åke LILJEQVIST
Original Assignee
Simplexia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Simplexia Ab filed Critical Simplexia Ab
Publication of CY1124824T1 publication Critical patent/CY1124824T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983Viruses
    • G01N33/56994Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16071Demonstrated in vivo effect
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01DNA viruses
    • G01N2333/03Herpetoviridae, e.g. pseudorabies virus
    • G01N2333/035Herpes simplex virus I or II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με μια πρωτεΐνη που περιλαμβάνει μια κολοβωμένη εκδοχή της πρωτεΐνης HSV - 2 mg G-2, όπου η εν λόγω πρωτεΐνη περιλαμβάνει: (i) μια εξωκυτταρική περιοχή mg G-2 (EX-mg G-2), ή μια κολοβωμένη εκδοχή αυτής, τουλάχιστον 285 αμινοξέων· όπου η εν λόγω εξωκυτταρική περιοχή ή η κολοβωμένη εκδοχή αυτής έχει τουλάχιστον 90 %, 95 %, 96 %, 97 %, 98 % ή 99 % ταυτοσημία αλληλουχίας (%SI) με ένα πεπτιδικό κλάσμα του αντίστοιχου μήκους που υπάρχει στην SEQ ID NO: 3· (ii) μια κολοβωμένη διαμεμβρανική περιοχή mg G-2 (t-TMR-mg G-2) 2 έως 15 αμινοξέων· όπου η εν λόγω κολοβωμένη διαμεμβρανική περιοχή έχει τουλάχιστον 90 % ταυτοσημία αλληλουχίας (%SI) με ένα πεπτιδικό θραύσμα του αντίστοιχου μήκους που υπάρχει στην SEQ ID NO: 6· και (iii) μια ενδοκυτταρική περιοχή mg G-2 (IC-mg G-2), ή μια κολοβωμένη εκδοχή αυτής, τουλάχιστον 18 αμινοξέων· όπου η εν λόγω ενδοκυτταρική περιοχή ή η κολοβωμένη εκδοχή αυτής έχει τουλάχιστον 90 % ή 95 % ταυτοσημία αλληλουχίας (%SI) με ένα πεπτιδικό θραύσμα του αντίστοιχου μήκους που υπάρχει στην SEQ ID NO: 8.
CY20211101118T 2016-02-01 2021-12-20 Κολοβωμενη γλυκοπρωτεϊνη g του ιου του απλου ερπητα 2 CY1124824T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE1650122 2016-02-01
PCT/EP2017/052070 WO2017134061A1 (en) 2016-02-01 2017-01-31 Truncated glycoprotein g of herpes simplex virus 2

Publications (1)

Publication Number Publication Date
CY1124824T1 true CY1124824T1 (el) 2022-11-25

Family

ID=57963202

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211101118T CY1124824T1 (el) 2016-02-01 2021-12-20 Κολοβωμενη γλυκοπρωτεϊνη g του ιου του απλου ερπητα 2

Country Status (15)

Country Link
US (1) US10654899B2 (el)
EP (1) EP3411388B1 (el)
CN (1) CN108779151B (el)
CA (1) CA3012267C (el)
CY (1) CY1124824T1 (el)
DK (1) DK3411388T3 (el)
ES (1) ES2900364T3 (el)
HR (1) HRP20211962T1 (el)
HU (1) HUE056866T2 (el)
LT (1) LT3411388T (el)
PL (1) PL3411388T3 (el)
PT (1) PT3411388T (el)
RS (1) RS62747B1 (el)
SI (1) SI3411388T1 (el)
WO (1) WO2017134061A1 (el)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471778A1 (en) 1989-05-12 1992-02-26 Ciba Corning Diagnostics Corp. Herpes simplex virus type 2-glycoprotein g proteins and polypeptides
WO1996017938A1 (en) 1994-12-06 1996-06-13 Bruschettini S.R.L. Glycoproteins from herpes virus and vaccines containing them
US5965354A (en) * 1995-07-28 1999-10-12 Chiron Corporation Herpes simplex virus diagnostics
GB9615533D0 (en) 1996-07-24 1996-09-04 Peptide Therapeutics Ltd Diagnostic test for herpes simplex virus type-2
EP1102790B1 (en) * 1998-08-07 2014-05-07 University of Washington Immunological Herpes Simplex Virus antigens and methods for use thereof
EP1536828B1 (en) * 2001-03-28 2013-06-05 President and Fellows of Harvard College Methods for delivery of exogenous proteins to the cytosol
NZ597182A (en) 2009-05-22 2014-07-25 Genocea Biosciences Inc Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
CN102573883A (zh) * 2009-06-12 2012-07-11 疫苗技术公司 用于促进细胞-介导的免疫应答的方法和组合物
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response

Also Published As

Publication number Publication date
EP3411388B1 (en) 2021-11-17
HRP20211962T1 (hr) 2022-03-18
PL3411388T3 (pl) 2022-04-04
US10654899B2 (en) 2020-05-19
PT3411388T (pt) 2021-12-20
DK3411388T3 (da) 2021-12-13
SI3411388T1 (sl) 2022-02-28
CA3012267C (en) 2023-09-19
HUE056866T2 (hu) 2022-03-28
CA3012267A1 (en) 2017-08-10
US20190031723A1 (en) 2019-01-31
CN108779151B (zh) 2022-12-13
ES2900364T3 (es) 2022-03-16
RS62747B1 (sr) 2022-01-31
EP3411388A1 (en) 2018-12-12
LT3411388T (lt) 2022-01-10
CN108779151A (zh) 2018-11-09
WO2017134061A1 (en) 2017-08-10

Similar Documents

Publication Publication Date Title
CY1124664T1 (el) Υποδοχεις τ λεμφοκυτταρων
PE20191551A1 (es) Polipeptidos de union al receptor de transferrina disenados
MX2022001134A (es) Proteinas quimericas de factor viii y usos de estas.
PE20190335A1 (es) Receptores de celulas t
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
CY1119916T1 (el) Ανοσογονικη συνθεση
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
CY1115140T1 (el) Πεπτιδια και η χρηση τους
EA201491049A1 (ru) Противораковый слитый белок
CY1126121T1 (el) Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων
ES2676023T3 (es) Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
BR112017019625A2 (pt) udp-glicosiltransferases
EA201992536A1 (ru) Tcr и пептиды
CY1120055T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
NO20063026L (no) Antistoffer
CY1123014T1 (el) Αναστολη των πεπτιδιων που προερχονται απο τον υποδοχεα ενεργοποιησης που εκφραζεται σε μυελοειδη κυτταρα-1 (trem-1) και το μεταγραφο τυπου trem 1 (tlt-1) και χρησεις αυτων
UA108778C2 (xx) Протираковий злитий протеїн
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
BR112016026842A2 (pt) preparação compreendendo fator viii e peptídeos de fator de von willebrand
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos
EA202190240A1 (ru) Варианты рекомбинантного белка
RU2022100555A (ru) Новый пептид